You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
On February 23, 2011, the Food and Drug Administration (FDA) granted approval for zidovudine 100 mg tablets, indicated for use in combination with other antiretrovirals for the treatment of HIV-1 infection. The tablets are intended for pediatric use and can be dispersed in water for all patients unable to swallow tablets.
The tablets are manufactured by Matrix Laboratories Limited of Hyderabad, India.
This product will not be marketed in the United States, where the oral syrup formulation serves pediatric dosing needs.
Zidovudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI) anti-viral drug indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
The application was reviewed under expedited review provisions for the President’s Emergency Plan for AIDS Relief (PEPFAR).
A list of all FDA approved and tentatively approved antiretrovirals for PEPFAR can be found on the FDA web site.
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
Manage your FDA Subscriptions:
- Update your preferences or unsubscribe
- Questions about this service? support@xxxxxxxxxxxxxxx
- Other inquiries? webmail@xxxxxxxxxx
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420
